A dual regulation of the expression of SREBP1 and its downstream effector SCD1 has been previously described in prostate cancer tissue specimens where high and low levels of SREBP1 and SCD1, respectively, have been detected (Ettinger et al, 2004; Moore et al, 2005). This evidence concerns the gene SCD and prostate carcinoma.